Aeglea BioTherapeutics (AGLE) Stock Price, News & Analysis

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AGLE shares.
View AGLE analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1-year price objectives for Aeglea BioTherapeutics' shares. Their AGLE share price targets range from $12.50 to $22.50. On average, they expect the company's share price to reach $17.50 in the next year.
View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its earnings results on Thursday, November, 4th. The biotechnology company reported ($7.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.00) by $0.75. The biotechnology company earned $1.40 million during the quarter, compared to the consensus estimate of $1.38 million. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%.

Aeglea BioTherapeutics shares reverse split on Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

Aeglea BioTherapeutics (AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.